

IMPROVING ADOPTIVE CELL THERAPY

MAY 30 & MAY 31, 2024

CENTRE DE RECHERCHE DES CORDELIERS


PARIS

Adoptive cell therapy, particularly CAR T-cell therapy, has marked a revolutionary milestone in the treatment of hematological malignancies and is now making strides in the realm of auto-immune diseases. However, for solid tumors, there remains a substantial path ahead.

This congress will delve into the critical aspects of optimizing adoptive cell therapy. The first segment will explore the host conditions for greater efficacy of adoptive cell therapy. Following this, a dedicated session will focus on T-cell engineering, and lastly, we will examine novel targets for CAR T-cell therapy.

The meeting is designed to provide networking between clinicians, scientists from academic and industrial partners in the field of cell therapies.

This event will bring together the foremost experts in immunology, oncology, and cellular therapy.



MAY 30, 2024

9 :00 Introduction, Prof Laurence Zitvogel

I.HOST

Moderators : Aymeric Silvin, Claudia Pasqualini

9:15 Yasmine Belkaid, National Institute of Health, USA; Institut Pasteur, France

TBD

9:45 Florent Ginhoux, Gustave Roussy, France

TBD

10:15 Jérôme Galon, Centre des Cordeliers, France

TBD

10:45 Cécile Alanio, Institut Curie, France

TBD

11:15 Julie Helft, Institut Cochin, France

TBD

11:45 Camille Bigenwald, Gustave Roussy, France

Host-dependant mechanisms of resistance to CAR T cells

BUFFET

II. TARGETING TUMOR ANTIGENS

Moderators: Florent Ginhoux, Laurie Menger

14:00 Robert Majzner, Stanford & Harvard, USA

TBD

14:30 Katy Rezvani, MD Anderson Cancer Center, USA

TBD

15:00 Sebastian Amigorena, Institut Curie, France

15:30 Alena Gros, Vall d'Hebron Institute of Oncology, Spain

BREAK

17:00 Short talks (2 best abstracts)

17:30 Posters teasing (1 min per poster)

18:00 Poster presentation & cocktail

MAY 31, 2024

III. T CELL ENGINEERING

Moderators: Camille Blériot, Camille Bigenwald

9:00 Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA

TBD

9:30 Alexander Marson, University of California San Francisco, USA

TBD

10:00 Justin Eyquem, University of California San Francisco, USA

TBD

10:30 Suman Mitra, Lille University Hospital, France

Modulating Cytokine Function for Enhanced Immunotherapies

BREAK

11:30 Rahul Roychoudhuri, University of Cambridge, England

12:00 Laurie Menger, Gustave Roussy, France

Advanced T-cell therapy using genome-scale CRISPR screens

12:30 Claire Roddie, University College London, UK

13:00 Luca Gattinoni, Leibniz Institute for Immunotherapy, Germany

13:30 Conclusion, Prof Guido Kroemer

Organizing Committee: Dr Camille Bigenwald, Dr Laurie Menger et Prof Laurence Zitvogel.